Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
AQST Aquestive Therapeutics	$4.02 -0.2%	$3.15	$2.12 ▼ $5.80	$400.29M	1.97	1.50 million shs	1.18 million shs
CKPT Checkpoint Therapeutics	$4.26	$4.23	$2.06 ▼ $4.50	$370.71M	1.18	1.53 million shs	N/A
FULC Fulcrum Therapeutics	$7.84 -0.8%	$6.80	$2.32 ▼ $10.13	$426.44M	2.37	909,706 shs	357,215 shs
TNYA Tenaya Therapeutics	$0.69 -3.0%	$0.55	$0.36 ▼ $4.06	$115.72M	3	2.74 million shs	2.42 million shs

Beginner's Guide To Retirement Stocks

Enter your email address and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
AQST Aquestive Therapeutics	-0.25%	+9.24%	+17.54%	+60.80%	+45.13%
CKPT Checkpoint Therapeutics	0.00%	0.00%	0.00%	+5.45%	+69.72%
FULC Fulcrum Therapeutics	-0.76%	-0.13%	+14.45%	+156.21%	-7.22%
TNYA Tenaya Therapeutics	-3.01%	+9.04%	+16.65%	+49.38%	-80.40%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
AQST Aquestive Therapeutics	2.1007 of 5 stars	3.5	3.0	0.0	3.4	0.0	0.0
CKPT Checkpoint Therapeutics	0.4601 of 5 stars	1.2	0.0	4.2	1.8	0.0	0.0
FULC Fulcrum Therapeutics	0.609 of 5 stars	1.3	2.0	0.0	2.1	2.5	0.0
TNYA Tenaya Therapeutics	3.4 of 5 stars	3.5	3.0	0.0	1.4	4.2	1.3

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
AQST Aquestive Therapeutics	3.00	Buy	$10.14	152.31% Upside
CKPT Checkpoint Therapeutics	2.33	Hold	$4.33	1.72% Upside
FULC Fulcrum Therapeutics	2.50	Moderate Buy	$6.29	-19.83% Downside
TNYA Tenaya Therapeutics	3.00	Buy	$6.25	805.80% Upside

Current Analyst Ratings Breakdown

Latest TNYA, FULC, CKPT, and AQST Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
6/17/2025	AQST Aquestive Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$10.00
6/2/2025	AQST Aquestive Therapeutics	Oppenheimer Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Outperform	$7.00
5/29/2025	FULC Fulcrum Therapeutics	Piper Sandler Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Overweight ➝ Overweight	$6.00 ➝ $9.00
5/23/2025	FULC Fulcrum Therapeutics	Leerink Partnrs Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Hold ➝ Strong-Buy
5/23/2025	FULC Fulcrum Therapeutics	Leerink Partners Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Market Perform ➝ Outperform	$4.00 ➝ $12.00
5/15/2025	AQST Aquestive Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$10.00 ➝ $10.00
5/15/2025	FULC Fulcrum Therapeutics	Cantor Fitzgerald Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Neutral ➝ Overweight	$10.00
5/9/2025	TNYA Tenaya Therapeutics	Chardan Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$9.00 ➝ $9.00
4/25/2025	TNYA Tenaya Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$5.00 ➝ $5.00

(Data available from 7/16/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
AQST Aquestive Therapeutics	$54.23M	7.36	N/A	N/A	($0.66) per share	-6.09
CKPT Checkpoint Therapeutics	$41K	9,041.59	N/A	N/A	($0.47) per share	-9.06
FULC Fulcrum Therapeutics	$80M	5.29	N/A	N/A	$4.51 per share	1.74
TNYA Tenaya Therapeutics	N/A	N/A	N/A	N/A	$1.07 per share	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
AQST Aquestive Therapeutics	-$44.14M	-$0.59	N/A	N/A	N/A	-100.02%	N/A	-50.31%	8/5/2025 (Estimated)
CKPT Checkpoint Therapeutics	-$51.85M	-$1.29	N/A	∞	N/A	N/A	N/A	-659.07%	8/11/2025 (Estimated)
FULC Fulcrum Therapeutics	-$9.73M	-$0.07	N/A	N/A	N/A	N/A	-0.20%	-0.19%	7/30/2025 (Estimated)
TNYA Tenaya Therapeutics	-$111.13M	-$1.16	N/A	N/A	N/A	N/A	-92.20%	-74.53%	8/14/2025 (Estimated)

Latest TNYA, FULC, CKPT, and AQST Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/11/2025	Q2 2025	CKPT Checkpoint Therapeutics	-$0.02	N/A	N/A	N/A	$7.28 million	N/A
8/5/2025	Q2 2025	AQST Aquestive Therapeutics	-$0.18	N/A	N/A	N/A	$11.32 million	N/A
7/30/2025	Q2 2025	FULC Fulcrum Therapeutics	-$0.29	N/A	N/A	N/A	N/A	N/A
5/13/2025	Q1 2025	CKPT Checkpoint Therapeutics	-$0.10	-$0.19	-$0.09	-$0.19	$4.53 million	N/A
5/12/2025	Q1 2025	AQST Aquestive Therapeutics	-$0.17	-$0.24	-$0.07	-$0.24	$12.23 million	$8.72 million
5/7/2025	Q1 2025	TNYA Tenaya Therapeutics	-$0.18	-$0.24	-$0.06	-$0.24	N/A	N/A
5/1/2025	Q1 2025	FULC Fulcrum Therapeutics	-$0.29	-$0.28	+$0.01	-$0.28	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
AQST Aquestive Therapeutics	N/A	N/A	N/A	N/A	N/A
CKPT Checkpoint Therapeutics	N/A	N/A	N/A	N/A	N/A
FULC Fulcrum Therapeutics	N/A	N/A	N/A	N/A	N/A
TNYA Tenaya Therapeutics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
AQST Aquestive Therapeutics	N/A	4.87	4.48
CKPT Checkpoint Therapeutics	N/A	0.29	0.29
FULC Fulcrum Therapeutics	N/A	28.71	28.71
TNYA Tenaya Therapeutics	N/A	6.68	6.68

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
AQST Aquestive Therapeutics	32.45%
CKPT Checkpoint Therapeutics	22.00%
FULC Fulcrum Therapeutics	89.83%
TNYA Tenaya Therapeutics	90.54%

Insider Ownership

Company	Insider Ownership
AQST Aquestive Therapeutics	7.85%
CKPT Checkpoint Therapeutics	2.10%
FULC Fulcrum Therapeutics	7.00%
TNYA Tenaya Therapeutics	48.65%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
AQST Aquestive Therapeutics	160	99.33 million	91.53 million	Optionable
CKPT Checkpoint Therapeutics	10	87.02 million	47.81 million	Optionable
FULC Fulcrum Therapeutics	100	53.98 million	50.20 million	Optionable
TNYA Tenaya Therapeutics	110	162.67 million	83.53 million	Optionable

TNYA, FULC, CKPT, and AQST Headlines

Recent News About These Companies

Brokerages Set Tenaya Therapeutics, Inc. (NASDAQ:TNYA) Price Target at $6.25

July 10, 2025 | americanbankingnews.com

TNYA - Tenaya Therapeutics Inc Dividends - Morningstar

July 8, 2025 | morningstar.comM

TNYA - Tenaya Therapeutics Inc Trailing Returns - Morningstar

July 8, 2025 | morningstar.comM

Tenaya Therapeutics, Inc. (NASDAQ:TNYA) Receives Consensus Rating of "Buy" from Analysts

July 7, 2025 | marketbeat.com

Tenaya Therapeutics (NASDAQ:TNYA) Stock Price Down 0.3% - Here's Why

July 4, 2025 | marketbeat.com

Tenaya Therapeutics, Inc. (TNYA) Balance Sheet - Yahoo Finance

June 27, 2025 | finance.yahoo.com

Tenaya Therapeutics, Inc. (TNYA) Cash Flow - Yahoo Finance

June 27, 2025 | finance.yahoo.com

Tenaya Therapeutics, Inc.: Tenaya Therapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)

May 16, 2025 | finanznachrichten.de

Tenaya Therapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)

May 15, 2025 | globenewswire.com

Why Tenaya Therapeutics, Inc.’s (TNYA) Stock Is Down 5.10%

May 15, 2025 | aaii.comA

Tenaya Therapeutics to Present Five Abstracts on Innovative Heart Disease Gene Therapies at ASGCT 2025 Annual Meeting

May 15, 2025 | nasdaq.com

Tenaya Therapeutics to Highlight Capsid Engineering, Gene Editing and Manufacturing Research at the ASGCT 28th Annual Meeting

May 13, 2025 | globenewswire.com

Analysts Offer Insights on Healthcare Companies: Vigil Neuroscience Inc (VIGL), Stevanato Group (STVN) and Tenaya Therapeutics (TNYA)

May 11, 2025 | theglobeandmail.com

We're A Little Worried About Tenaya Therapeutics' (NASDAQ:TNYA) Cash Burn Rate

May 10, 2025 | finance.yahoo.com

Tenaya Therapeutics Reports Q1 2025 Financial Results

May 8, 2025 | tipranks.com

Tenaya Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Update

May 7, 2025 | finance.yahoo.com

Why Tenaya Therapeutics, Inc.’s (TNYA) Stock Is Up 5.03%

May 2, 2025 | aaii.comA

Why Tenaya Therapeutics, Inc.’s (TNYA) Stock Is Down 6.21%

April 30, 2025 | aaii.comA

H.C. Wainwright maintains Buy on Tenaya Therapeutics stock

April 26, 2025 | investing.com

Why Tenaya Therapeutics, Inc.’s (TNYA) Stock Is Up 6.36%

April 26, 2025 | aaii.comA

Tenaya announces interim data from ongoing RIDGE study

April 25, 2025 | markets.businessinsider.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

TNYA, FULC, CKPT, and AQST Company Descriptions

Aquestive Therapeutics NASDAQ:AQST

$4.02 -0.01 (-0.25%)

Closing price 07/15/2025 04:00 PM Eastern

Extended Trading

$3.99 -0.03 (-0.75%)

As of 07/15/2025 07:53 PM Eastern

Aquestive Therapeutics, Inc. operates as a pharmaceutical company in the United States and internationally. The company markets Sympazan, an oral soluble film formulation of clobazam for the treatment of lennox-gastaut syndrome; Suboxone, a sublingual film formulation of buprenorphine and naloxone for the treatment of opioid dependence; Zuplenz, an oral soluble film formulation of ondansetron for the treatment of nausea and vomiting associated with chemotherapy and post-operative recovery; and Azstarys, a once-daily product for the treatment of attention deficit hyperactivity disorder. Its proprietary product candidates comprise Libervant, a buccal soluble film formulation of diazepam for the treatment of seizures; KYNMOBI, a sublingual film formulation of apomorphine for the treatment of episodic off-periods in Parkinson's disease; and Exservan, an oral soluble film formulation of riluzole for the treatment of amyotrophic lateral sclerosis. The company's proprietary pipeline of complex molecule product includes AQST-108, a sublingual film formulation delivering systemic epinephrine for the treatment of conditions other than anaphylaxis; and Anaphylm, an epinephrine sublingual film for the emergency treatment of allergic reactions, including anaphylaxis. In addition, it develops Adrenaverse, an epinephrine prodrug platform. The company was incorporated in 2004 and is headquartered in Warren, New Jersey.

Checkpoint Therapeutics NASDAQ:CKPT

Checkpoint Therapeutics, Inc., a clinical-stage immunotherapy and targeted oncology company, focuses on the acquisition, development, and commercialization of novel treatments for patients with solid tumor cancers in the United States and internationally. The company's lead antibody product candidate is Cosibelimab, which is in Phase 1 clinical trial to treat patients with selected recurrent or metastatic cancers; and CK-302, a product candidate in preclinical trials for hematological malignancies and solid tumors. It is developing Olafertinib, which is in Phase 3 clinical trials for the treatment of adult patients with metastatic non-small cell lung cancer; CK-103 for the treatment of various advanced and metastatic solid tumor cancers; and Anti-Carbonic Anhydrase IX (CAIX) antibody, a product candidate in preclinical trials to recognize CAIX expressing cells and kill them via antibody-dependent cellular cytotoxicity and complement-dependent cytotoxicity. The company has licensing and collaboration agreements with Adimab, LLC for the development of Cosibelimab; NeuPharma, Inc., to develop and commercialize Olafertinib; and Jubilant Biosys Limited for the development and commercialization of novel compounds that inhibit BET bromodomains. The company was incorporated in 2014 and is based in Waltham, Massachusetts. Checkpoint Therapeutics, Inc. is a subsidiary of Fortress Biotech, Inc.

Fulcrum Therapeutics NASDAQ:FULC

$7.84 -0.06 (-0.76%)

Closing price 07/15/2025 04:00 PM Eastern

Extended Trading

$7.84 0.00 (0.00%)

As of 07/15/2025 04:24 PM Eastern

Fulcrum Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing products for improving the lives of patients with genetically defined diseases in the areas of high unmet medical need in the United States. Its product candidates are losmapimod, a small molecule for the treatment of facioscapulohumeral muscular dystrophy is under phase III clinical trial; and pociredir, a fetal hemoglobin inducer for the treatment of sickle cell disease and beta-thalassemia is under phase I clinical trial. The company is also discovering drug targets for the treatments of rare neuromuscular, muscular, central nervous system, and hematologic disorders, as well as cardiomyopathies and pulmonary diseases. Fulcrum Therapeutics, Inc. has collaboration and license agreement with Acceleron Pharma Inc. to identify biological targets to modulate specific pathways associated with a targeted indication within the pulmonary disease space; and MyoKardia, Inc. to discover and develop therapies for the treatment of genetic cardiomyopathies. Fulcrum Therapeutics, Inc. was Incorporated in 2015 and is headquartered in Cambridge, Massachusetts.

Tenaya Therapeutics NASDAQ:TNYA

$0.69 -0.02 (-3.01%)

Closing price 07/15/2025 04:00 PM Eastern

Extended Trading

$0.69 0.00 (0.00%)

As of 07:30 AM Eastern

Tenaya Therapeutics, Inc., a biotechnology company, discovers, develops, and delivers therapies for heart disease in the United States. It develops its products through gene editing, cellular regeneration, and gene addition. The company is developing TN-201, a gene therapy for myosin binding protein C3-associated hypertrophic cardiomyopathy which is in phase 1 clinical trial; TN-301, a small molecule for heart failure with preserved ejection fraction which is in phase 1 clinical trial; and TN-401, a gene therapy for plakophilin 2-associated arrhythmogenic right ventricular cardiomyopathy which is in preclinical stage. It also develops an adeno-associated virus-based gene therapy designed to deliver the dworf gene for patient with dilated cardiomyopathy; and reprogramming program for heart failure due to prior myocardial infarction. Tenaya Therapeutics, Inc. was incorporated in 2016 and is headquartered in South San Francisco, California.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time